Related Experiment Videos

Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure

N D Vaziri1, C H Kim, B Dang

  • 1Division of Nephrology and Hypertension, University of California, Irvine, Orange, CA 92868, USA. ndvaziri@uci.edu

Insights

Chronic renal failure (CRF) diminishes hepatic triglyceride synthesis by downregulating diglycerol acyltransferase (DGAT) gene expression and activity. This finding suggests reduced liver triglyceride production in CRF, contrary to previous assumptions.

Area of Science:

  • Nephrology
  • Biochemistry
  • Molecular Biology

Background:

  • Chronic renal failure (CRF) is linked to hypertriglyceridemia and elevated VLDL/IDL, potentially due to altered lipoprotein metabolism.
  • Previous research focused on reduced clearance of triglyceride-rich lipoproteins in CRF.
  • The impact of CRF on hepatic triglyceride synthesis remained unexplored.

Purpose of the Study:

  • To investigate the effect of CRF on diglycerol acyltransferase (DGAT) gene expression and activity in the liver.
  • To determine if CRF alters the hepatic triglyceride biosynthesis pathway.

Main Methods:

  • Male Sprague-Dawley rats underwent 5/6 nephrectomy (CRF) or sham operation.
  • Liver samples were analyzed for DGAT-1 and DGAT-2 mRNA abundance.
  • Hepatic DGAT activity was quantified.

Main Results:

  • CRF rats exhibited reduced creatinine clearance and elevated plasma triglycerides and VLDL.
  • Significant reductions in hepatic DGAT-2 mRNA abundance (P < 0.01) were observed in CRF rats.
  • Total hepatic DGAT activity showed a significant decrease (P < 0.1) in CRF animals.

Conclusions:

  • CRF leads to significant downregulation of hepatic DGAT gene expression and activity.
  • This indicates a diminished hepatic triglyceride production capacity in CRF.
  • The study suggests reduced, not increased, hepatic triglyceride synthesis in CRF rats.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...